HANA EL SAHLY to Aged
This is a "connection" page, showing publications HANA EL SAHLY has written about Aged.
Connection Strength
0.354
-
Central Nervous System Histoplasmosis: A Retrospective Review of Clinical Characteristics, Treatments and Outcomes With Comparison to Disseminated Histoplasmosis Without Central Nervous System Involvement. Mycoses. 2025 May; 68(5):e70068.
Score: 0.063
-
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021 Nov 04; 385(19):1774-1785.
Score: 0.049
-
MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines. 2010 Oct; 9(10):1135-41.
Score: 0.023
-
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials. J Infect Dis. 2024 Dec 16; 230(6):1384-1389.
Score: 0.015
-
SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir. J Infect Dis. 2024 Sep 23; 230(3):624-634.
Score: 0.015
-
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases. Nat Commun. 2024 Aug 29; 15(1):7469.
Score: 0.015
-
COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials. Clin Infect Dis. 2024 08 16; 79(2):364-374.
Score: 0.015
-
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials. JAMA Netw Open. 2024 05 01; 7(5):e2412835.
Score: 0.015
-
The effect of mannose binding lectin gene polymorphisms on susceptibility to tuberculosis in different ethnic groups. Scand J Infect Dis. 2004; 36(2):106-8.
Score: 0.014
-
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials. JAMA Netw Open. 2023 07 03; 6(7):e2323349.
Score: 0.014
-
Mycobacterium simiae pseudo-outbreak resulting from a contaminated hospital water supply in Houston, Texas. Clin Infect Dis. 2002 Oct 01; 35(7):802-7.
Score: 0.013
-
Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022 03 17; 386(11):1046-1057.
Score: 0.013
-
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022 Jan 07; 375(6576):43-50.
Score: 0.012
-
Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65?years and older. Vaccine. 2021 02 22; 39(8):1339-1348.
Score: 0.012
-
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 02 04; 384(5):403-416.
Score: 0.012
-
Epidemiologic differences between United States- and foreign-born tuberculosis patients in Houston, Texas. J Infect Dis. 2001 Feb 01; 183(3):461-8.
Score: 0.012
-
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 03 04; 384(9):795-807.
Score: 0.012
-
Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74?years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2018 01 29; 36(5):606-614.
Score: 0.009
-
Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 2015 Jan 01; 33(1):163-73.
Score: 0.008
-
Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults. Vaccine. 2014 Oct 29; 32(47):6284-93.
Score: 0.008
-
Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old. Vaccine. 2009 Dec 11; 28(2):379-85.
Score: 0.005